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Available online 2 August 2016Fibrodysplasia ossiﬁcans progressiva (FOP) is a rare and devastating genetic disease of heterotopic endochondral
ossiﬁcation (HEO), and currently no effective therapies are available for this disease. A recurrent causative het-
erozygousmutation (c.617 GNA; R206H) for FOPwas identiﬁed in activin receptor type IA (ACVR1), a bonemor-
phogenetic protein (BMP) type I receptor. This mutation aberrantly activates the BMP-Smad1/5/8 signaling
pathway and leads to HEO in FOP patients. Here we report development of a soluble recombinant ACVR1-Fc fu-
sion protein by combining the extracellular domain of human wild type ACVR1 and the Fc portion of human im-
munoglobulin gamma 1 (IgG1). The ACVR1-Fc fusion protein signiﬁcantly down-regulated the dysregulated BMP
signaling caused by the FOP ACVR1 mutation and effectively suppressed chondro-osseous differentiation in a
previously described cellular FOP model, human umbilical vein endothelial cells (HUVECs) that were infected
with adenovirus-ACVR1R206H (HUVECR206H). This ACVR1-Fc fusion protein holds great promise for prevention
and treatment of HEO in FOP and related diseases.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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ALK21. Introduction
Fibrodysplasia ossiﬁcans progressiva (FOP; OMIM#135100) is a rare
and disabling genetic disorder characterized by cumulative episodes of
progressive heterotopic endochondral ossiﬁcation (HEO) [1–3]. Ap-
proximately 97% of individuals with FOP have a recurrent heterozygous
activating mutation (c.617GNA; p.R206H) in the intracellular glycine-
serine-rich (GS) domain of ACVR1, also known as activin receptor-like
kinase 2 (ALK2), a bone morphogenetic protein (BMP) type I receptor
[2–5]. This mutation disrupts the interaction of ACVR1 with FKBP1A
(also known as FKBP-12) which normally prevents leaky BMP type I re-
ceptor activation in the absence of BMP ligand, leading to aberrant acti-
vation of BMP signaling [6,7]. Despite its mild constitutive activity,
ACVR1R206H and the various FOP genotypic variants are also exquisitely
ligand sensitive [2,8]. Therefore, inhibition of ligand binding to ACVR1 is
a plausible strategy to abrogate dysregulated BMP pathway signaling
and disrupt disease-speciﬁc phenotypic changes of ectopic chondrogen-
esis and osteogenesis in FOP.ology and Metabolism, Tongji
Xincun Road, Putuo district,
. This is an open access article underCurrently, no established effective therapy is available for FOP and
present treatments are palliative [9–13]. Recently, small molecule
BMP type I receptor kinase inhibitors have been developed to target
ACVR1 [14–18]. However, these compounds exhibit “off-target” effects
on closely related kinases, raising side effect and safety concerns [19].
In addition, the RNA interference approach has been proposed to nor-
malize the excessive ACVR1 activity by speciﬁcally targeting mutant
ACVR1 [20–23]. However, application of RNA interference therapy is
currently limited for delivery of effector molecules into patients due to
their poor stability, non-targeted bio-distribution, and stimulation of
undesirable innate immune responses [24]. Recently, a retinoic acid re-
ceptor-γ (RAR-γ) agonist, palovarotene, entered Phase 2 clinical trials
for FOP [25]. Although this drug targets the obligate chondrogenic pro-
cess of HEO, concerns regarding undesirable effects, such as on normal
skeletal development in children with FOP, remain.
Recently, clinical evaluations indicated that FOP ﬂare-ups occur pre-
dominantly in response to spontaneous myositis or tissue injury, sug-
gesting that speciﬁc ligands may activate ACVR1 during the
inﬂammatory process [2,3]. Therefore, reagents to competitively bind
the ligands or block their access to their cognate receptors represent a
novel therapy to FOP.
Obtaining biopsies from FOP patients may cause disease ﬂare-ups,
therefore therapeutic reagents for FOP are often evaluated initially inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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endothelial cells [21], ADTC5 cells expressing ALK2Q207D [25], C2C12
cells expressing ACVR1R206H [6], or mouse embryonic ﬁbroblasts [26].
Recently,Medici reported [27] that HUVECs infectedwith adenovirus car-
rying the ACVR1R206H gene transformed into multipotent stem-like cells
and gained the ability to differentiate into osteoblasts and chondrocytes,
representing an excellent human cell in vitromodel to evaluate therapeu-
tic agents for preventing heterotopic ossiﬁcation in FOP. In this article, we
report a novel ACVR1 fusionproteinACVR1-Fc that attenuates the dysreg-
ulated BMP pathway signaling and effectively suppresses osteogenic and
chondrogenic differentiation potential in HUVECR206H cells. The hypothe-
sis for ACVR1-Fc working mechanism is expressed in Fig. 1.2. Materials and methods
2.1. Materials and reagents
The CHO DG44 cell line (A11000-01, Life Technology, Carlsbad, CA,
USA)was grown inCDDG44medium(12610-010, Life Technology, Carls-
bad, CA, USA). OptiCHO medium (12681-011, Life Technology, Carlsbad,
CA, USA) was used for the CHO DG44-ACVR1-Fc cells. HUVECs (CRL-
1730, ATCC, Manassas, VA, USA) were cultured in EGM (endothelial
growth medium-2, CC-3162, Lonza, Walkersville, MD, USA) containing
10% fetal bovine serum (FBS, 10099-141, Gibco, Grand Island, NY, USA)
and 1% penicillin-streptomycin (15070-063, Gibco, Grand Island, NY,
USA). L-glutamine (G3126, Sigma, Saint Louis, MO, USA), Methotrexate
(MTX, M9929, Sigma, Saint Louis, MO, USA), AP-conjugated anti-human
IgG1 Fc antibody (109-055-098, Jackson ImmunoResearch Lab, West
Grove, PA, USA), pNPP (0201–01, Southern biotech, Birmingham, Ala-
bama, USA), NotI (1166A, Takara, Japan) and XbaI (1093A, Takara,
Japan) were used.Fig. 1. Diagram of potential mechanism of the ACVR1-Fc fusion protein. ACVR1 is a single-tran
binding domains. The ACVR1 ligands that contribute to the pathogenesis of FOP are not fully d
extracellular domain of receptor is responsible for bindingwith ligands, therefore an ACVR1-Fc
IgG1 is predicted to act as a trap to bind disease-activating ligands.2.2. Construction of the Ad-ACVR1R206H adenovirus
the ACVR1 mutation (cDNA 617G→617A) was generated by site-di-
rected mutagenesis of the human ACVR1 cDNA (GenBank NM_001105).
The mutated ACVR1 DNA was joined to pIRES2-EGFP (Invitrogen, Carls-
bad, CA, USA) and inserted into the PMD18-T Simple Vector (Takara,
Japan) to generate the recombinant plasmid. Next, the recombinant plas-
mid was inserted into pAd CMV/V5-DEST (Invitrogen, Carlsbad, CA, USA)
to generate the ACVR1R206H-IRES-GFP (Ad-ACVR1R206H) adenovirus. The
Ad-ACVR1 (WT) was constructed in a similar way. The constructs were
veriﬁed by sequence analysis, and protein expression was conﬁrmed by
EGFP detection. The virus titer was determined to be 1 × 1010 ifu/ml in
293A cells.
2.3. Generation of the HUVECR206H cells
HUVEC cells were transferred to low serum medium (Human Endo-
thelial-Serum Free Medium (11111-044, Gibco, Grand Island, NY, USA),
containing 2% FBS, 1% penicillin-streptomycin and 10 ng/ml EGF
(PHG0313, Gibco, Grand Island, NY, USA), 20 ng/ml bFGF (PHG0261,
Gibco, Grand Island, NY, USA) for 24 h. The recombinant adenovirus
ACVR1R206H-IRES-GFP (Ad-ACVR1R206H) was administrated to the
HUVECs at MOI 200.
2.4. Assays for chondrogenesis and osteogenesis
After growth in chondrogenic medium (A10071-01, Gibco StemPro
chondrogenic medium, Grand Island, NY, USA) for 14 days, the HUVEC-
R206H cells were washed and ﬁxed with 4.0% formaldehyde, then
incubated with 0.3% Alcian blue 8GX (A5268, Sigma, Saint Louis, MO,
USA) to evaluate chondrogenic differentiation by detecting sulfatedsmembrane receptor consisting of intracellular, transmembrane, and extracellular ligand-
eﬁned, and more than one type of ligand may contribute to this process. Theoretically, the
fusion protein that is composed of the extracellular domain of ACVR1 and the Fc portion of
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HUVECs transfected by Ad-ACVR1(WT) were used as controls for this
experiment.
To evaluate the potential osteogenic differentiation of the HUVEC-
R206H, both alkaline phosphatase (ALP) and Alizarin red S staining
were performed after 7 days and 21 days incubation in osteogenic in-
duction medium (A10072-01, StemPro osteogenic medium, Gibco,
Grand Island, NY, USA), respectively. For alkaline phosphatase staining
(SK-5300, Vector, Burlingame, CA, USA), the HUVECR206H cells were
washed with PBS and ﬁxed with 4.0% formaldehyde followed by
30 min of substrate incubation as recommended by the manufacturer's
instructions (Vector, Burlingame, CA, USA). Next, the cells werewashed
with 100 mM Tris-HCl (T1503, Sigma, Saint Louis, MO, USA) buffer
(pH 8.2) and examined under bright-ﬁeld microscopy. For Alizarin red
S staining and detection of matrix calciﬁcation, the cells were washed
with PBS and ﬁxed with 4.0% formaldehyde, then stained with 1% Aliz-
arin red S (pH 4.2) (A5533, Sigma, Saint Louis,MO, USA) for 10min. Im-
ages were captured under bright-ﬁeld microscopy. HUVECs transfected
by Ad-ACVR1(WT) were used as controls for those experiments.
2.5. Cloning of recombinant ACVR1-Fc mammalian expression vector
TheDNA sequence encoding the humanACVR1 extracellular domain
from amino acids 21 to 123 (UniProt: Q04771) was synthesized by
Genewiz (China), and the sequence encoding the Fc region of human
IgG1 was synthesized by Genscript (China). The cDNA encoding the
ACVR1-Fc fusion protein was constructed in a 3-step set of PCR reac-
tions. The ﬁrst step consisted of three rounds of ampliﬁcation of cDNA
encoding the signal peptide, the extracellular domain region of the
human ACVR1 protein, and the hinge (CH2 and CH3 domains of the Fc
region of human IgG1, respectively). Primers for these PCR reactions
are partially complementary at the 5′ ends of the adjacent fragments
which were then fused to create the chimeras. The primers, CMV-F
(5′-CGCAAATGGGCGGTAGGCGTG) and Signal-R (5′- AGCCAGGGCCCC
TGCC), were used to amplify the signal peptide region from a cDNA
plasmid (Kanda Biotech, Shanghai, China); the primers, ACVR1-F (5′-
GGGCAGGGGCCCTGGCTATGGAGGACGAGAAGCCC) and ACVR1-R (5′-
TATCACAGCTCTTGGGCTCCTCCAGGTGGAAGTTCTGGG), were used to
amplify the gene region encoding the ACVR1 extracellular domain;
the primers, IgG Fc-F (5′- GAGCCCAAGAGCTGTGATA) and BGH-R (5′-
AACTAGAAGGCACAGTCGAGGC) were used to amplify the IgG1 Fc re-
gion. Next, the signal peptide-encoding cDNA was fused to the 5′ end
of the cDNA encoding the ACVR1 extracellular domain using CMV-F as
a forward primer and ACVR1-R as a reverse primer in an over-lapped
extension PCR. The ﬁnal step consisted of an over-lapped extension
PCR of the cDNA generated in step 2 and the cDNA encoding IgG1 Fc re-
gion. The ﬁnal fusion PCR fragment was cut with NotI and XbaI (these
sites were introduced in the ﬁrst step PCRs) and inserted into themam-
malian expression vector, pKD1.2 (KandaBiotech, Shanghai, China). The
correct construct was conﬁrmed by DNA sequencing.
2.6. Generation of stable transfected cell lines and fusion protein production
A stable CHO DG44-ACVR1-Fc cell line was established by
transfecting the ACVR1-Fc expression vector into the host DG44 cells
followed by methotrexate (MTX) antibiotic selection. In brief, 1 × 107
DG44 cells were electroporated with 100 μg linearized ACVR1-Fc ex-
pression vector by using a Bio-Rad Gene Pulser II electroporator (Bio-
Rad) at a 270 V/950 uF capacitance setting. After 24-hour incubation,
the cells were serially diluted and cultured in 96-well plates in OptiCHO
selection medium containing 100 nM MTX for additional three weeks.
To determine ACVR1-Fc expression, the culture media from each well
were analyzed by ELISA by using alkaline phosphatase-conjugated
goat anti-human IgG Fc antibody. Cell clones producing higher levels
of the fusion protein were expanded and stepwise exposed to higher
concentrations of MTX (up to 500 nM). Finally, the stable CHO DG44-ACVR1-Fc cell line was established by selecting a cell clone with the
highest level of ACVR1-Fc fusion protein production.
2.7. Puriﬁcation and characterization of the ACVR1-Fc fusion protein
Culture medium supernatant from the fusion protein-producing cell
line was passed over a protein-A Sepharose column (AKTA-FPLC sys-
tem) and bound proteins were eluted in 20 mM acid citrate (pH 3.6)
followed by immediate neutralization with 0.1 volumes of 10× PBS
(pH 7.0). The fusion protein was further puriﬁed by a Superdex-200
under standard conditions and analyzed on SDS-polyacrylamide gel
electrophoresis (SDS-PAGE).
2.8. Atomic absorption analysis
To quantify the calcium content of the cell layer after osteogenic in-
duction for 21 days, the HUVECs were washed with PBS (Ca2+ and
Mg2+ free) 3 times, and lysed with 0.1% Triton X-100/10 mM Tris-HCl
(pH 7.5). The cell extracts were then decalciﬁed with 11.6 N HCl at
room temperature for 16 h. After centrifugation, the supernatant was
collected to detect calcium concentration by Atomic Emission Spec-
trometer (Agilent, 7200) [28]. Themaximal suppression rate ofmineral-
ization was calculated as the following formula: (the calcium content in
the treated control HUVECs minus the calcium content in the treated
HUVECsR206H)/the calcium content in the control HUVECs.
2.9. Western blot analysis
Western blot analysis was used to detect protein expression levels of
osteogenic/chondrogenic markers and phosphorylation of Smad1/5/8
and p38MAPK. HUVECR206H cells were harvested and mechanically ho-
mogenized after osteogenic/chondrogenic induction for 9 days. RIPA
buffer containing protease inhibitors (phenylmethylsulfonyl ﬂuoride)
was added to cell extracts, and protein concentrationswere determined
by BCA ProteinAssay Kit (P0009, Beyotime, China). The cell lysateswere
separated by SDS-PAGE and transferred to 0.45 μm PVDF membranes
(IPVH08130, Millipore, Billerica, MA, USA). The PVDF membranes
were then treated with blocking buffer (P0023B, Beyotime, China) at
room temperature for 1.5 h followed by incubations with primary anti-
bodies speciﬁc for osteogenesis/chondrogenesis markers and signaling
proteins at manufacturer's recommended concentrations. The primary
antibodies include GAPDH (AG019-1, Beyotime, China), osteocalcin
(ab133612, abcam, Cambridge, MA, USA), Osterix (ab22552, abcam,
Cambridge, MA, USA), Runx2 (ab76956, abcam, Cambridge, MA, USA),
Collagen I (ab138492, abcam, Cambridge, MA, USA), Collagen II
(ab3092, abcam, Cambridge, MA, USA), smad1 (9743, Cell Signaling
Technology, Danvers,MA, USA), phospho-Smad1/5/8 (9511, Cell Signal-
ing Technology, Danvers, MA, USA), p38MAPK (8690, Cell Signaling
Technology, Danvers, MA, USA), phospho-p38MAPK (9215, Cell Signal-
ing Technology, Danvers, MA, USA). Secondary antibodies used were
Peroxidase-conjugated afﬁniPure goat anti-rabbit and goat anti-mouse
IgG (Jackson Immunoresearch Laboratories, 111-035-003, 1:5000 dilu-
tion). The immunoreactive protein bands were visualized by ECL Plus
(1305701, Millipore, Billerica, MA, USA) western blotting detection sys-
tem. ACVR1-Free Fc (Chimerigen Laboratories, China) was used as the
negative control.
2.10. Elisa
Activin A, BMP-2, BMP-5, BMP-6, and BMP-7were all human recom-
binant proteins purchased fromPeproTech. 96-well ELISA plates (Nunc)
were coated with 100 ng of a cytokine in 50 μl of 200 mM NaHCO3
(pH 9.6) coating buffer at 4 °C overnight. The next day, the plates
were washed 3 times with PBS containing 0.05% Tween-20 (wash buff-
er) followed by blocking with 100 ul/well of 3% BSA in wash buffer at
37 °C for 2 h. The blocking solution was replaced with binding buffer
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teins, followed by 2-hour incubation at 37 °C. Next the plates were
washed 3 times with the wash buffer, and 50 μl diluted alkaline phos-
phatase-conjugated goat anti-human IgG1 antibody (1:3000) was
added to each well. After another 2-hour incubation at 37 °C, the plates
were washed again and added 50 μl of PNPP substrate solution (South-
ern Biotech). Finally the plates were read at double wavelength 405 nm
and 490 nm using a microplate reader (iMax, Bio-Rad). The non-coated
wells were used as negative controls.
2.11. Statistical analysis
The independent sample t-test was performed using SPSS 21.0 soft-
ware. Results are expressed asmean± SD. p values b 0.05were consid-
ered statistically signiﬁcant.
3. Results
3.1. The HUVECR206H cellular model functionally reproduces dysregulated
chondro-osteogenesis of FOP in vitro
HUVECR206H cells were previously reported to gain properties of
multipotent stem-like cells, including the ability to differentiate into os-
teoblasts and chondrocytes, representing a good in vitro model for FOP
studies [27]. We therefore established this cellular model in our lab and
veriﬁed the differentiation ability of the HUVECR206H cells. To generate
the HUVECR206H cells and control cells, we ﬁrst constructed Ad-ACVR1-
R206H and Ad-ACVR1 (WT) adenovirus as detailed inMethod Section 2.2
(Fig. 2a), and then infected HUVECs with the constructed viruses. Both
the HUVECR206H and the control cells were GFP-positive, indicating the
successful virus infection (Fig. 2b and c; control cells not shown).
To evaluate their differentiation capacity, HUVECR206H cells were
cultured in chondrogenic or osteogenic media followed by analysis ofFig. 2. Development and characterization of HUVECR206H cells as a model for FOP chondrogeni
adenovirus carrying ACVR1R206H cDNA [ACVR1(M)] or wild type ACVR1 cDNA [ACVR1(WT
adenovirus-ACVR1R206H infection; (d–e) Alcian blue staining for HUVECs infected with A
differentiation; (f–g) ALP staining for HUVECs infected with Ad-ACVR1(WT) (panel f) or Ad-A
for HUVECs infected with Ad-ACVR1(WT) (panel h) or Ad-ACVR1R206H (panel i) after 21 dayschondrogenic and osteogenic markers, respectively. On day 14, the
HUVECR206H cells cultured under chondrogenic conditions stained pos-
itively with Alcian blue for the highly sulfated proteoglycans character-
istic of functional chondrocytes (Fig. 2e), suggesting that HUVECR206H
cells are able to differentiate into chondrocytes. The osteogenic differen-
tiation of HUVECR206H cells was conﬁrmed by both alkaline phosphatase
(ALP) staining (Fig. 2g) and alizarin red staining (Fig. 2i). In contrast, the
control cells, HUVECs infected with Ad-ACVR1 (WT), failed to differen-
tiate to either chondrogenic or osteogenic lineages as indicated by
Alcian blue, ALP and alizarin red staining (Fig. 2d, f and h). In summary,
we established that the HUVECR206H in vitro model functionally repro-
duces the chondro-osteogenesis phenotype conferred by dysregulated
ACVR1 in FOP.3.2. Develop the ACVR1-Fc fusion protein
To investigatewhether targetingACVR1-binding ligands could effec-
tively suppress the effects of the ACVR1R206H mutation, we constructed
a cDNA encoding anACVR1 -Fc fusion protein comprised of the extracel-
lular domain of human ACVR1 (amino acids Met21-Glu123) and a
human IgG1 constant region (Glu99-Lys330). We then inserted the
cDNA into themammalian expression vector pKD1.2, whichwas subse-
quently transfected into DG44 cells to establish stably transfected
DG44-ACVR1-Fc cells. The recombinant ACVR1-Fc protein was pro-
duced in the established cell line with a yield of approximately
400mg/l and puriﬁed by protein-A afﬁnity chromatography (see Mate-
rials and methods). The puriﬁed protein migrated as a dimer with the
expected mass 80 kDa under non-reducing conditions, and as a mono-
mer at the expected 40 kDa under reducing conditions (Fig. 3a). In addi-
tion, the HPLC-SEC (Superdex-200) proﬁle showed a major single peak
with a retention volume corresponding to a molecular mass of about
80 kDa (Fig. 3b).c and osteogenic induction. (a) Schematic of the plasmid constructs and the recombinant
)]; (b) HUVECs under light microscopy; (c) GFP reporter expression in HUVECs after
d-ACVR1(WT) (panel d) or Ad-ACVR1R206H (panel e) after 14 days of chondrogenic
CVR1R206H (panel g) after 7 days of osteogenic differentiation; (h–i) Alizarin red staining
of osteogenesis differentiation. Scale bar = 200 μm.
Fig. 3. ACVR1-Fc fusion protein puriﬁcation and biochemical characterization. (a) SDS-PAGE analysis of ACVR1-Fc fusion protein samples under reducing or non-reducing conditions. (b)
HPLC-SEC mass molecular determination of native fusion protein. The molecular mass of the homodimer fusion protein was ~80 kDa on elution, based on comparison with the indicated
standards.
Fig. 4. The ACVR1-Fc fusion protein binds to BMP ligands and inhibits BMP signaling. (a) ELISA assays tomeasure in vitro binding of recombinant protein ACVR1-Fc withmembers of TGF-
beta superfamily. ELISA plates were coated with 100 ng of each ligand and incubated with varying concentration of ACVR1-Fc protein. Each ligand-ACVR1-Fc binding was assayed in
duplicate. (b) Western blotting demonstrated that 5 μg/ml ACVR1-Fc signiﬁcantly decreased phosphorylation of Smad1/5/8 and p38MAPK; quantiﬁcations are shown in (c and d).
Western blotting experiments were performed in triplicate, and error bars in ﬁgures represent mean ± SD. ⁎⁎⁎indicates statistical differences (p b 0.001) vs. control group by the
independent samples t-test.
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tively inhibits BMP signaling
Various ligands including BMP2, BMP5, BMP6 and BMP7 are known
to induce BMP signaling via ACVR1 as a type I receptor [29,30]. In addi-
tion, Activin A was recently reported to activate the Smad-dependent
BMP signaling via FOP ACVR1R206H [8,31].We therefore examined bind-
ing of the ACVR1-Fc to those ligands by ELISA. Our results showed that
ACVR1-Fc strongly bound BMP-5 (EC50 = 0.25 μM) and BMP-6
(EC50 = 0.47 μM), but displayed weak binding capacity for Activin A,
BMP-2 and BMP-7.
Next we examined whether the ACVR1-Fc protein can effectively
suppress BMP signaling in the HUVECR206H cells. Our study showed
that 5 μg/ml ACVR1-Fc robustly down-regulated phosphorylated
Smad1/5/8 and p38MAPK levels to 37% and 38% of the expression levels
of the control Fc-treated groups, respectively (Fig. 4b, c and d).
3.4. ACVR1-Fc inhibits chondro-osseous differentiation in HUVECR206H cells
To examine effects of ACVR1-Fc on chondro-osseous differentiation,
we treated HUVECR206H cells with the ACVR1-Fc protein in osteogenic
and chondrogenic differentiation media. A range of concentrations of
ACVR1-Fc protein was examined in a preliminary study (data not
shown), and 2.5 μg/ml and 5 μg/ml ACVR1-Fc were selected for use in
further studies since the ACVR1-Fc protein worked effectively at these
concentrations without notable detrimental effects on cells. Under
chondrogenic conditions, Alcian blue staining was signiﬁcantly de-
creased in the ACVR1-Fc-treated group compared to the control Fc-
treated group (Fig. 5a, d and g). The proportion of HUVECR206H cellsFig. 5. The ACVR1-Fc fusion protein inhibits osteogenic and chondrogenic differentiation in HUV
evaluated inHUVECR206H cells byAlcianblue staining (a, d andg), and on osteogenic differentiat
experiment was performed in triplicate.) Compared with the 5 μg/ml Fc fragment treated cont
treated with ACVR1-Fc 2.5 μg/ml (d–f) or ACVR1-Fc 5 μg/ml (g–i). (j) Atomic absorption analys
with ACVR1-Fc at 2.5 μg/ml or 5 μg/ml or control-Fc at 5 μg/ml. (k)Western blotting showed th
Collagen I (Col-I), Osterix (Osx), and Runx2, and the chondrogenic marker Collagen II (ColII)
⁎⁎⁎indicates statistical differences (p b 0.001) vs. control group.positive for ALP staining also signiﬁcantly decreased in the ACVR1-Fc-
treated group (Fig. 5b, e and h). Similarly, under osteogenic conditions,
alizarin red staining for mineralized nodules was also dramatically
down-regulated in the ACVR1-Fc-treated groups in comparison to the
control group (Fig. 5c, f and i).
To further conﬁrm the inhibitory effects of the ACVR1-Fc protein on
chondro-osseous differentiation, we detected osteogenic and
chondrogenic protein marker expression in the HUVECR206H cells by
Western blot analyses. Our results showed that treatment with
ACVR1-Fc fusion protein signiﬁcantly inhibited both osteogenic and
chondrogenic protein levels in the HUVECR206H cells (Fig. 5k and l).
For osteogenic markers, 5 μg/ml ACVR1-Fc fusion protein signiﬁcantly
reduced osteocalcin, collagen I, osterix, and Runx2 to 33% ±1%,
36% ± 5%, 42% ± 4%, and 30% ± 3% of the corresponding levels in the
ACVR1-Free Fc-treated control groups, respectively. In addition, expres-
sion of the chondrogenic marker collagen II in the 5 μg/ml ACVR1-Fc
treated groupwasdecreased to 42%±14%of the ACVR1-Free Fc-treated
control groups (all the control levels were set as 100%).
Mineralization of extracellular osteoid is a characteristic feature of
mature osteogenic differentiation. We used atomic absorption analysis
of total calcium content, including both intracellular calcium and extra-
cellular matrix calcium, to evaluate the osteogenic capacity in the
HUVECR206H model system. Under standard osteogenic conditions, the
calcium content of HUVECR206H cells was 52.75 ± 1.00 mg/l (mean ±
SD) in the control group, but dramatically dropped to 37.25 ± 0.71 in
2.5 μg/ml ACVR1-Fc-treated group and to 25.87 ± 0.49 in the 5 μg/ml
ACVR1-Fc-treated group (Fig. 5j), indicating that the ACVR1-Fc fusion
protein treatment decreased the cellular mineralization in a dose-de-
pendent manner (p b 0.001 vs. control). Taken together, the ACVR1-FcECR206H cells. Effects of the ACVR1-Fc fusion protein on chondrogenic differentiation were
ion byALP staining (b, e and h) andAlizarin red staining (c, f and i). (Scale bar: 200 μm. Each
rol group (a–c), the proportion of positively stained cells signiﬁcantly decreased in groups
is for the total calcium content after 21 days of osteogenic induction in the groups treated
at ACVR1-Fc (5 μg/ml) reduced the expression of the osteogenic markers Osteocalcin (OC),
. The western blotting bands were quantiﬁed and are shown in (l). Scale bar = 200 μm.
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tion in the HUVECR206H model system (Fig. 5g-l).
4. Discussion
FOP is a rare but devastating genetic disorder of extra-skeletal bone
formation, and presently no effective treatment is available. To address
this issue, we developed a soluble ACVR1-Fc protein as a ligand trap for
ACVR1. The inhibitory effects of the ACVR1-Fc protein on FOPmutation-
induced chondro-osseous differentiation were evaluated in the stem
cell-like HUVECR206H in vitro system [27]. Our data demonstrated that
the ACVR1-Fc protein effectively binds to ACVR1 cognate ligands such
as BMP5 and BMP6, and down-regulates phosphorylation of Smads1/
5/8 as well as non-canonical p38MAPK signaling pathways. Cytochem-
ical staining andWestern blot analyses conﬁrmed the inhibitory effects
of the ACVR1-Fc protein on chondro-osseous differentiation. Atomic ab-
sorption analysis further demonstrated that ACVR1-Fc inhibited the
dysregulated ACVR1-dependent functional effects on osteogenicminer-
alization. In summary, our study demonstrates that ACVR1-Fc inhibits
dysregulated BMP signaling and attenuates chondro-osseous differenti-
ation in an FOP in vitro model by binding to the ACVR1 cognate ligands.
Although several in vitro cellular models, including HUVECR206H,
have been previously reported in FOP studies, the speciﬁc cell type(s)
that originate the HEO process in FOP remains unknown. Numerous re-
ports have supported that endothelial cells participate in theHOprocess
under the inﬂuence of the FOP mutation [27,32] while other data
indiciate that a muscle resident population of non-endothelial cells
may be responsible for osteogenesis in the acquired HEO [33]. In vivo
data for either possibility as progenitors in hereditaryHEO remains lack-
ing. However, both our study and previous reports demonstrated that
the HUVECR206H cells can transdifferentiate into osteoblasts and
chondrocytes, thus providing a useful in vitro system. The speciﬁc li-
gands that induce such transdifferentiation remain unknown, however,
the ACVR1-Fc protein exhibits strong binding to BMP5 and BMP6 and
blocks HUVECR206H transdifferentiation, implicating these ligands in
this process. Further investigation to examine this hypothesis is
warranted.
Despite the widely-held misconception that the recurrent common
ACVR1R206H mutation is constitutively active in FOP, the data support
that this gain-of-function mutation only mildly activates BMP signaling
in the absence of ligand and is highly responsive to ligands [8,34]. This
study conﬁrms that the canonical FOP mutation is exquisitely ligand
sensitive. Such ﬁndings are consistent with the episodic nature of dis-
ease activity in FOP as well as with evanescent and trauma-induced li-
gand stimulation. Cumulative studies have supported that the mutant
ACVR1 receptor is more responsive to BMP ligands and that blocking
BMPs can inhibit HEO [4,35,36]. Interestingly, two groups recently re-
ported that activin A, a ligand which normally antagonizes BMP signal-
ing via wild type (WT) ALK2, activates BMP pathway signaling through
the FOP ALK2 mutant receptor [8,31]. Based on the cumulative litera-
ture, it is likely that both BMP ligands and activin A contribute HEO in
FOP. This idea is further supported by our recent discovery that BMP6
mRNA expression in blood mononuclear cells was signiﬁcantly higher
in FOP patients than that in the age and sex-matched healthy control
groups (unpublished data). Therefore, blocking both BMPs- and activin
A-induced BMPpathway activation appears to be a promising therapeu-
tic approach to FOP, and ourACVR1-Fc fusion proteinmay be on optimal
strategy to attenuate BMP pathway signaling induced by ACVR1-re-
sponsive ligands during HEO formation in FOP.
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